Adimmune Corporation

TWSE:4142 Stock Report

Market Cap: NT$8.5b

Adimmune Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Steve Chan

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure16.5yrs
CEO ownershipn/a
Management average tenure10.2yrs
Board average tenure7.6yrs

Recent management updates

Recent updates

Little Excitement Around Adimmune Corporation's (TWSE:4142) Revenues

Aug 13
Little Excitement Around Adimmune Corporation's (TWSE:4142) Revenues

Shareholders Can Be Confident That Adimmune's (TPE:4142) Earnings Are High Quality

Apr 05
Shareholders Can Be Confident That Adimmune's (TPE:4142) Earnings Are High Quality

Is Adimmune (TPE:4142) Using Debt In A Risky Way?

Mar 01
Is Adimmune (TPE:4142) Using Debt In A Risky Way?

Introducing Adimmune (TPE:4142), The Stock That Zoomed 158% In The Last Three Years

Jan 07
Introducing Adimmune (TPE:4142), The Stock That Zoomed 158% In The Last Three Years

CEO Compensation Analysis

How has Steve Chan's remuneration changed compared to Adimmune's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-NT$608m

Jun 30 2024n/an/a

-NT$608m

Mar 31 2024n/an/a

-NT$575m

Dec 31 2023n/an/a

-NT$640m

Sep 30 2023n/an/a

-NT$165m

Jun 30 2023n/an/a

-NT$9m

Mar 31 2023n/an/a

NT$277m

Dec 31 2022n/an/a

NT$291m

Sep 30 2022n/an/a

NT$525m

Jun 30 2022n/an/a

NT$267m

Mar 31 2022n/an/a

NT$58m

Dec 31 2021NT$67mNT$7m

NT$43m

Sep 30 2021n/an/a

NT$989m

Jun 30 2021n/an/a

NT$988m

Mar 31 2021n/an/a

NT$1b

Dec 31 2020NT$31mNT$7m

NT$1b

Compensation vs Market: Insufficient data to establish whether Steve's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

CEO

Steve Chan

16.5yrs

Tenure

NT$67,320,000

Compensation

Mr. Chi-Hsien Chan, also known as Steve, is Chairman of Adimmune Corporation since 2008 and has been its Director and Chief Executive Officer since July 01, 2008. Mr. Chan holds position of Chairman of Hem...

Leadership Team

NamePositionTenureCompensationOwnership
Chi-Hsien Chan
CEO & Chairman16.5yrsNT$67.32mno data
Chung-Cheng Liu
President12.1yrsNT$4.65mno data
Chin-Chuan Chang
COO and VP of R&D10.2yrsNT$5.74mno data
Fei Pan
Chief Legal Officer & General Counsel12.8yrsNT$5.25m0.025%
NT$ 2.1m
Yin-Teng Chang
Chief Financial Officer4yrsno datano data
Li-Ya Tang
Director of Administration Center9.4yrsno datano data
Chih-Hsiang Leng
Head of R&D Division5.8yrsno datano data
Chin-I Chiu
Vice President of Quality Assurance Departmentno dataNT$5.63mno data

10.2yrs

Average Tenure

Experienced Management: 4142's management team is seasoned and experienced (10.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Chi-Hsien Chan
CEO & Chairman16.5yrsNT$67.32mno data
Chung-Cheng Liu
President5.6yrsNT$4.65mno data
Wei-Kuang Chi
Director23.6yrsNT$35.00kno data
Jung-Chin Lin
Director5.6yrsNT$35.00kno data
Chi-Heng Lin
Director16.3yrsNT$35.00k0.0012%
NT$ 100.8k
Chien-Fu Chen
Director7.6yrsNT$35.00kno data
Mei-Hsing Tseng
Director7.6yrsNT$35.00kno data
Hsiao-Po Hsu
Independent Director13.4yrsNT$3.00mno data
Mei-Hsiang He
Independent Director7.6yrsNT$995.00kno data
Yung-Sheng Hsu
Independent Director4.6yrsNT$875.00kno data
Der-Sheng Lin
Institutional Director1.2yrsno datano data
Mei-Ling Hsiao
Independent Directorless than a yearno datano data

7.6yrs

Average Tenure

Experienced Board: 4142's board of directors are considered experienced (7.6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/02 04:35
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Adimmune Corporation is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jianzheng WuCapital Securities Corporation
Zhennan LeeJih Sun Securities Investment Consulting Co., Ltd.
Hengyu FuMasterlink Securities Corp.